Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19
Status:
Not yet recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This randomized open labeled clinical trial will include one hundred healthy healthcare
workers who will be randomly assigned into four groups of twenty-five each to receive either
levamisole, Isoprinosine, combined levamisole and isoprinosine or no-intervention for two
months to detect the impact of Levamisole and Isoprinosine as immune-prophylaxis on the
incidence of COVID-19 infection. Participants will be followed-up for three months clinically
and laboratory. Blood samples will be collected prior to randomization and during follow up.